BridgeBio Oncology Therapeutics

Historical price data

BridgeBio Oncology Therapeutics (BBOT) is a focused, public subsidiary of BridgeBio Pharma, established to conquer RAS-driven cancers through a novel, dual-pathway inhibition strategy. The company's mission is to translate deep biological insights into therapies that directly inhibit the active, GTP-bound state of RAS mutants and the PI3Kα pathway, a key resistance mechanism. Its strategy leverages the operational and financial infrastructure of its parent company to advance a targeted pipeline aimed at significant markets in pancreatic, colorectal, and lung cancers. While still in early clinical stages, BBOT represents a scientifically rigorous contender in the rapidly evolving post-KRAS G12C inhibitor landscape.

A biology-driven platform focused on designing small molecule inhibitors that target the active, GTP-bound state of RAS mutants and develop RAS-selective PI3Kα inhibitors to achieve vertical pathway inhibition and overcome resistance.

BBOT competes with approved KRAS G12C inhibitors (Amgen, Mirati), next-generation direct RAS players like Revolution Medicines (more advanced clinically), and numerous PI3Kα and downstream pathway developers. Its differentiation lies in its dual-pathway, biology-focused strategy and BridgeBio's operational support, but it is a later-stage entrant in a fast-moving field.